211 related articles for article (PubMed ID: 35074557)
21. Post-transplant сyclophosphamide after matched donor hematopoietic stem cell transplantation in children with acute leukemia.
Borovkova AS; Paina OV; Semenova EV; Bykova TA; Osipova AA; Slesarchuk OA; Kozhokar PV; Tsvetkova LA; Rakhmanova ZZ; Kozlov AV; Chukhlovin AB; Kazantsev IV; Estrina MA; Goloshchapov OV; Bondarenko SN; Moiseev IS; Kulagin AD; Zubarovskaya LS
Clin Transplant; 2024 Jan; 38(1):e15181. PubMed ID: 37922213
[TBL] [Abstract][Full Text] [Related]
22. Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome.
Singh A; Dandoy CE; Chen M; Kim S; Mulroney CM; Kharfan-Dabaja MA; Ganguly S; Maziarz RT; Kanakry CG; Kanakry JA; Patel SS; Hill JA; De Oliveir S; Taplitz R; Hematti P; Lazarus HM; Abid MB; Goldsmith SR; Romee R; Komanduri KV; Badawy SM; Friend BD; Beitinjaneh A; Politikos I; Perales MA; Riches M
Transplant Cell Ther; 2022 Jan; 28(1):48.e1-48.e10. PubMed ID: 34587551
[TBL] [Abstract][Full Text] [Related]
23. Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC.
Bailén R; Pascual-Cascón MJ; Guerreiro M; López-Corral L; Chinea A; Bermúdez A; Sampol A; Heras I; García-Torres E; Torres M; Roca JR; Herruzo B; Sanz J; Fonseca M; Herrera P; Colorado M; Bento L; López-Godino O; Martín-Calvo C; Fernández-Caldas P; Marcos-Jubilar M; Sánchez-Ortega I; Solano C; Noriega V; Humala K; Oarbeascoa G; Díez-Martín JL; Kwon M;
Transplant Cell Ther; 2022 Apr; 28(4):204.e1-204.e10. PubMed ID: 35108627
[TBL] [Abstract][Full Text] [Related]
24. Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation.
Chhabra S; Jerkins JH; Monahan K; Szabo A; Shah NN; Abedin S; Runaas L; Fenske TS; Pasquini MC; Shaw BE; Drobyski WR; Saber W; D'Souza A; Dhakal B; Mohan M; Longo W; Hamadani M
Bone Marrow Transplant; 2024 Mar; 59(3):373-379. PubMed ID: 38177221
[TBL] [Abstract][Full Text] [Related]
25. Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD.
Maurer K; Ho VT; Inyang E; Cutler C; Koreth J; Shapiro RM; Gooptu M; Romee R; Nikiforow S; Antin JH; Wu CJ; Ritz J; Soiffer RJ; Kim HT
Blood Adv; 2023 Aug; 7(15):3903-3915. PubMed ID: 37156098
[TBL] [Abstract][Full Text] [Related]
26. PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT.
Salas MQ; Charry P; Pedraza A; Martínez-Cibrian N; Solano MT; Domènech A; Suárez-Lledó M; Nomdedeu M; Cid J; Lozano M; de-LLobet N; Arcarons J; Rosiñol L; Gutiérrez-García G; Carreras E; Esteve J; Urbano-Ispizua Á; Fernández-Avilés F; Rovira M; Martínez C
Transplant Cell Ther; 2022 Aug; 28(8):489.e1-489.e9. PubMed ID: 35577323
[TBL] [Abstract][Full Text] [Related]
27. Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.
Mehta RS; Saliba RM; Ghanem S; Alousi AM; Rondon G; Anderlini P; Al-Atrash G; Bashir Q; Hosing CM; Im JS; Kebriaei P; Khouri I; Marin D; Nieto Y; Olson A; Oran B; Popat UR; Qazilbash MH; Ramdial J; Saini N; Srour SA; Champlin RE; Rezvani K; Shpall EJ
Transplant Cell Ther; 2022 Jul; 28(7):395.e1-395.e11. PubMed ID: 35513252
[TBL] [Abstract][Full Text] [Related]
28. Incidence and Impact of Fungal Infections in Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis and Haploidentical Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Papanicolaou GA; Chen M; He N; Martens MJ; Kim S; Batista MV; Bhatt NS; Hematti P; Hill JA; Liu H; Nathan S; Seftel MD; Sharma A; Waller EK; Wingard JR; Young JH; Dandoy CE; Perales MA; Chemaly RF; Riches M; Ustun C
Transplant Cell Ther; 2024 Jan; 30(1):114.e1-114.e16. PubMed ID: 37775070
[TBL] [Abstract][Full Text] [Related]
29. Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide.
Rappazzo KC; Zahurak M; Bettinotti M; Ali SA; Ambinder AJ; Bolaños-Meade J; Borrello I; Dezern AE; Gladstone D; Gocke C; Fuchs E; Huff CA; Imus PH; Jain T; Luznik L; Rahmat L; Swinnen LJ; Wagner-Johnston N; Jones RJ; Ambinder RF
Transplant Cell Ther; 2021 Nov; 27(11):909.e1-909.e6. PubMed ID: 34425261
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation.
Nakamae H; Nakane T; Okamura H; Koh H; Nakashima Y; Hirose A; Nakamae M; Nishimoto M; Kuno M; Makuuchi Y; Harada N; Takakuwa T; Hino M
Int J Hematol; 2022 Jan; 115(1):77-86. PubMed ID: 34586587
[TBL] [Abstract][Full Text] [Related]
31. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation.
Bailén R; Kwon M; Pascual-Cascón MJ; Ferrà C; Sanz J; Gallardo-Morillo A; García-Sola A; Torrent A; Jiménez-Lorenzo MJ; Piñana JL; Montoro J; Oarbeascoa G; Dorado N; Gómez-Centurión I; Muñoz C; Martínez-Laperche C; Anguita J; Buño I; Díez-Martín JL;
Ann Hematol; 2021 Feb; 100(2):541-553. PubMed ID: 33140137
[TBL] [Abstract][Full Text] [Related]
32. Posttransplant cyclophosphamide beyond haploidentical transplantation.
Arcuri LJ; Ribeiro AAF; Hamerschlak N; Kerbauy MN
Ann Hematol; 2024 May; 103(5):1483-1491. PubMed ID: 37261557
[TBL] [Abstract][Full Text] [Related]
33. Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors.
Solh MM; Baron J; Zhang X; Bashey A; Morris LE; Holland HK; Solomon SR
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2082-2088. PubMed ID: 32745575
[TBL] [Abstract][Full Text] [Related]
34. Effect of CD34
Pedraza A; Salas MQ; Rodríguez-Lobato LG; Charry P; Suárez-Lledo M; Martínez-Cibrian N; Doménech A; Solano MT; Arcarons J; de Llobet N; Rosiñol L; Gutiérrez-García G; Avilés FF; Urbano-Ispízua Á; Rovira M; Martínez C
Transplant Cell Ther; 2023 Mar; 29(3):181.e1-181.e10. PubMed ID: 36526259
[TBL] [Abstract][Full Text] [Related]
35. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Arcuri LJ; Aguiar MTM; Ribeiro AAF; Pacheco AGF
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2422-2430. PubMed ID: 31386903
[TBL] [Abstract][Full Text] [Related]
36. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation.
Shah MV; Saliba RM; Rondon G; Chen J; Soebbing D; Rus I; Alousi A; Oran B; Kebriaei P; Qazilbash M; Parmar S; Hosing C; Khouri IF; Popat UR; Champlin RE; Ciurea SO
Bone Marrow Transplant; 2019 Apr; 54(4):601-606. PubMed ID: 30337700
[TBL] [Abstract][Full Text] [Related]
37. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source.
Sterling CH; Hughes MS; Tsai HL; Yarkony K; Fuchs EJ; Swinnen LJ; Paul S; Bolaños-Meade J; Luznik L; Imus PH; Ali SA; Jain T; Ambinder A; DeZern A; Huff CA; Gocke CB; Varadhan R; Wagner-Johnston N; Jones RJ; Ambinder RF
Transplant Cell Ther; 2023 Apr; 29(4):267.e1-267.e5. PubMed ID: 36549386
[TBL] [Abstract][Full Text] [Related]
39. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors.
Montoro J; Piñana JL; Hernández-Boluda JC; Hernani R; Lorenzo I; Pérez A; Guerreiro M; Balaguer-Rosello A; Sanz GF; Carretero C; Albert E; Navarro D; Sanz MA; Solano C; Sanz J
Bone Marrow Transplant; 2020 Nov; 55(11):2147-2159. PubMed ID: 32371901
[TBL] [Abstract][Full Text] [Related]
40. Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type.
Mehta RS; Marin D; Alousi A; Kanakry CG; Champlin RE; Rezvani K; Shpall EJ; Page K; Gadalla SM; Weisdorf D; Kebriaei P
Blood Adv; 2023 Apr; 7(8):1594-1603. PubMed ID: 36630564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
